- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00248209
Female Orgasmic Disorder (FOD) and Wellbutrin XL
A Multi-center, Double-blind, Placebo-controlled Study of Bupropion XL in Females With Orgasmic Disorder
Study Overview
Detailed Description
Background:
Female orgasmic disorder is characterized by a recurrent or persistent difficulty in achieving orgasm during sexual activity. A study of sexual activity in a representative sample of the US population ages 18-59 found that 24% of US females complained of significant difficulty achieving orgasm in the preceding year (Laumann et al, 2000). Epidemiological studies in Sweden and the United Kingdom have found similar rates of orgasm disorder.
Studies of drugs with actions of increasing genital vasodilation in response to sexual stimulation (eg alprostadil, sildenafil, or phentolamine) have generally been found to be unsuccessful or to have extremely limited efficacy in reversing female sexual dysfunction (Basson, 2001; Segraves, 2002). High doses of androgen have been shown to increase various parameters of sexual interest and activity in women after hysterectomy and bilateral oophorectomy (Schifren et al, 2000) and there is some evidence that oral dehydroepiandrosterone may increase responsiveness to sexual stimuli in postmenopausal women (Hackbert & Heiman, 2002).
There have been fewer studies of pharmacological treatment for hypoactive sexual desire disorder in premenopausal women. Extensive literature indicates that bupropion has a very low incidence of drug-induced sexual dysfunction (Clayton et al, 2002; Croft et al, 1999; Segraves & Balon, 2003) and that bupropion may reverse sexual dysfunction associated with serotonergic antidepressants (Rosen et al, 1999; Kennedy et al, 2002). In addition one controlled study (Crenshaw et al, 1987) and several clinical series indicate that bupropion may have prosexual effects in non-depressed females (Modell et al, 2000). A single blind study (Segraves et al, 2001) found that bupropion increased the frequency of episodes of sexual arousal and desire for sexual activity in women diagnosed with hypoactive sexual desire disorder.
A recent multicenter, double-blind, fixed dose study of females with global, acquired hypoactive sexual desire disorder found evidence that an exposure to 300 to 400 mg bupropion XL increased orgasm and pleasure as measured by the CSFQ-F. In this pilot study, all women had total serum testosterone levels within normal limits and were in stable, non-conflictual relationships. All patients had no evidence of psychiatric disorder and no evident etiology to their sexual complaint. All were pre-menopausal. The pilot study observed the effects of drug treatment for four months. Significant change in measures of sexual orgasm occurred as early as day 28. There are no currently approved pharmacological treatments for women with orgasmic disorder.
Specific Aims:
The purpose of this study is to delineate the effects of bupropion XL in women with global orgasmic disorder, using double blind conditions in an 8 week flexible dose multisite comparison of bupropion XL and placebo. It is hypothesized that bupropion XL will increase orgasm completion.
The primary objective of this study is to evaluate the effect of bupropion XL on the ease and frequency of achieving orgasm in sexual activity.
Secondary objectives will be to investigate the effects of bupropion XL on changes in sexual arousal and sexual pleasure.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44109
- MetroHealth Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
A subject must:
- Be able to understand and sign a written informed consent
- Be a premenopausal female between 20 and 50 years of age, inclusive
- Use active birth control, and be non-lactating, with a negative urine pregnancy test
- Have no evidence of mood or anxiety disorder
- Have a sexual partner who is without sexual dysfunction
- Be in a stable, monogamous, sexual relationship of at least 6 months duration, and be willing to engage in sexual activity with a steady partner once a week for the duration of the study
- Have no active psychiatric diagnosis
- Have FOD which is not secondary to hypoactive sexual desire disorder or dyspareunia
- Have English as first language or be fluent in English language
Meet operational definition of global female orgasmic disorder:
- Frequency of orgasm during sexual activity of less than 50% of sexual encounters
- Presence of disorder for at least six months
- At least 3 orgasms achieved in past 6 months
- Have Beck Anxiety Disorder (BAI) scores less than 10
- Have Beck Depression Inventory-II (BDI-II) scores less than 10
- Have a CSFQ orgasm score of less than 11
- Patient may have female arousal disorder as well as female orgasmic disorder
Exclusion Criteria:
- Presence of organic condition known to cause sexual dysfunction (multiple sclerosis, diabetes mellitus, spinal cord injury)
Presence of hypoactive sexual desire disorder as defined below:
- Frequency of subjective sexual desire (interest in any type of sexual activity) less than or equal to once every two weeks
- Low intensity of sexual desire
- Frequency of self-initiated sexual activity less than or equal to once every two weeks
- Absence or low frequency of thoughts about sex (do not include thoughts of wishing for return of sexual interest): thoughts less than or equal to 4 times per month
- Presence of disorder for at least six months
- Absence of sexual desire includes all types of sexual activity
- Taking psychiatric drugs other than study medication (zolpidem can be taken for a total of 10 days in trial for nighttime sedation)
- Significant marital discord
- Presence of sexual aversion disorder, dyspareunia, vaginismus, gender identity disorder, paraphilia
- Drug or alcohol abuse in past year
- History of seizure disorder or significant head injury
- History of anorexia or bulimia
- Taking any pharmacological agents known to be associated with sexual dysfunction (chronic opiate use, beta-blockers, alpha-adrenergic blockers, psychotropic medications)
- Have an onset of orgasmic disorder within two months of beginning current hormonal contraceptive agent, if applicable
- Have a cessation of menses for the three consecutive months prior to study entry
- History of bilateral oophorectomy
- Presence of dyspareunia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Wellbutrin XL or placebo
1 arms - Wellbutrin XL or placebo
|
Patients randomized to the bupropion treatment group will receive bupropion XL150 mg in the AM for 7 days increasing to 300mg/day (single daily dose).
The investigator can increase the dose to 450mg per day at Day 28 if clinically indicated.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary objective of this study is to evaluate the effect of bupropion XL on the ease and frequency of achieving orgasm in sexual activity.
Time Frame: 8 weeks of treatment
|
8 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Secondary objectives will be to investigate the effects of bupropion XL on changes in sexual arousal and sexual pleasure.
Time Frame: 8 weeks of treatment
|
8 weeks of treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Robert T Segraves, MD, PhD, Metrohealth Medical Center/Case Western Reserve University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Disease
- Sexual Dysfunctions, Psychological
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Dopamine Agents
- Cytochrome P-450 Enzyme Inhibitors
- Antidepressive Agents, Second-Generation
- Cytochrome P-450 CYP2D6 Inhibitors
- Dopamine Uptake Inhibitors
- Bupropion
Other Study ID Numbers
- GSK FOD
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Orgasmic Disorder
-
Universidad Rey Juan CarlosCompleted
-
Acerus Pharmaceuticals CorporationCompletedFemale Orgasmic DisorderUnited States, Canada, Australia
-
Center for Vulvovaginal DisordersUnknownFemale Orgasmic DisorderUnited States
-
Hannover Medical SchoolCompletedSexual Arousal Disorder | Orgasmic Disorder | Restless Genital Syndrome | Psychosexual DisorderGermany
-
University of Texas at AustinEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMajor Depressive Disorder | Post-traumatic Stress Disorder | Hypoactive Sexual Desire Disorder | Female Orgasmic Disorder | Female Sexual Arousal DisorderUnited States
-
Cedars-Sinai Medical CenterCompletedUrinary Incontinence | Sexual Dysfunction | Pelvic Organ Prolapse | Pelvic Floor Disorders | Interstitial Cystitis | Female Sexual Dysfunction | Hypoactive Sexual Desire Disorder | Sexuality | Orgasmic Disorder | Sexual Desire DisorderUnited States
-
Adams ClinicalRecruitingGeneralized Anxiety Disorder | Major Depressive Disorder | Borderline Personality DisorderUnited States
-
Samsung Medical CenterUnknownMajor Depressive Disorder, Anxiety DisorderKorea, Republic of
-
Baylor College of MedicineRecruitingGeneralized Anxiety Disorder | Panic Disorder | Panic Disorder With Agoraphobia | Separation Anxiety | Anxiety Disorder of Childhood | Panic Attacks | Social Anxiety Disorder of Childhood | Obsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceUnited States
-
University of Illinois at ChicagoNational Institute of Mental Health (NIMH)RecruitingMood Disorders | Major Depressive Disorder | Bipolar Disorder I | Bipolar Disorder II | Persistent Depressive Disorder (Dysthymia) | CyclothymiaUnited States
Clinical Trials on Wellbutrin XL
-
NovartisCompletedMetabolic SyndromeTurkey
-
DePuy OrthopaedicsCompletedTotal Hip Arthroplasty | Adverse Local Tissue ReactionUnited States
-
Massachusetts General HospitalCompleted
-
St. Luke's-Roosevelt Hospital CenterGlaxoSmithKlineCompleted
-
Teva Pharmaceuticals USATerminatedDepressive DisorderUnited States
-
AlyatecCompletedAsthma | AllergyFrance
-
University of Rochester NCORP Research BaseNational Cancer Institute (NCI)RecruitingBe Diagnosed With Cancer and Have Completed Systemic TherapyUnited States
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH); University of OttawaCompleted
-
Massachusetts General HospitalCompletedMultiple MyelomaUnited States
-
Massachusetts General HospitalExelixisCompletedBile Duct Cancer | Intrahepatic Cholangiocarcinoma | Cholangiocarcinoma of the Extrahepatic Bile DuctUnited States